Effects of losartan on vasoconstrictor responses to angiotensin I in the forearm vascular bed of healthy volunteers

Cardiovascular Research

Volumn 32, Issue 5, 1996, Pages 973-979

  Baan Jr , Jan ^a,b   Chang, Peter C ^b   Vermeij, Pieter ^b   Pfaffendorf, Martin ^a   Van Zwieten, Pieter A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

angiotensin II; angiotensin receptor; human; losartan; vascular resistance

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR; LOSARTAN; LOSARTAN POTASSIUM;

ADULT; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; INTRAARTERIAL DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VASOCONSTRICTION;

ADMINISTRATION, ORAL; ADULT; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; DEPRESSION, CHEMICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FOREARM; HUMANS; IMIDAZOLES; INFUSIONS, INTRA-ARTERIAL; LOSARTAN; MALE; PLETHYSMOGRAPHY; RECEPTORS, ANGIOTENSIN; TETRAZOLES; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS;

EID: 0030296402     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/0008-6363(96)00133-2     Document Type: Article

References (31)

1. [1] Timmermans PB, Wong PC, Chiu AT, Herblin WF, Smith RD. New perspectives in angiotensin system control. J Hum Hypertens 1993;7:S19-S31.
2. [2] Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-251.
3. [3] Webb DJ, Collier JG. Vascular angiotensin conversion in humans. J Cardiovasc Pharmacol 1986;8:S40-S44.
4. [4] Cockcroft JR, Sciberras DG, Goldberg MR, Ritter JM. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol 1993;22:579-584.
5. [5] Christ DD, Kilkson T, Wong N, Lam G. Formation and disposition of EXP3174, a pharmacologically active metabolite of the novel angiotensin II receptor antagonist DuP 753. Proc Int Soc Study Xenobiotica, 1990, San Diego.
6. [6] Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174, an active metabolite of DuP 753 - an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;255:211-217.
7. [7] Chang PC, van Brummelen P. Calibration and variability of forearm blood flow, measured by strain-gauge plethysmography. J Cardiovasc Pharmacol 1987;10:S123-S125.
8. [8] Bruning TA, Hendriks MG, Chang PC, Kuypers EA, van Zwieten PA. In vivo characterization of vasodilating muscarinic-receptor subtypes in humans. Circ Res 1994;74:912-919.
9. [9] Timmermans PB, Smith RD. Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur Heart J 1994;15:79-87.
10. [10] Zhang J, Pfaffendorf M, van Zwieten PA. Hemodynamic effects of angiotensin II and the influence of angiotensin receptor antagonists in pithed rabbits. J Cardiovasc Pharmacol 1995;25:724-731.
11. + and depolarization favor angiotension tachyphylaxis in rabbit aorta. Am J Physiol 1991;260:H373-H378.
12. [12] Ito S, Johnson CS, Carretero OA. Modulation of angiotensin II-induced vasoconstriction by endothelium-derived relaxing factor in the isolated microperfused rabbit afferent arteriole. J Clin Invest 1991;87:1656-1663.
13. [13] Kuttan SC, Sim MK. Angiotensin II-induced tachyphylaxis in aortas of normo-and hypertensive rats: changes in receptor affinity. Eur J Pharmacol 1993;232:173-180.
14. [14] Robertson MJ, Wragg A, Clark KL. Modulation of tachyphylaxis to angiotensin II in rabbit isolated aorta by the angiotensin AT1 receptor antagonist, losartan. Regul Peptides 1994;50:137-145.
15. [15] Sim MK, Radhakrishnan R. In vivo study of angiotensin II tachyphylaxis in freely moving normo-and hypertensive rats. Pharmacol Toxicol 1994;74:223-227.
16. [16] Benjamin N, Cockcroft JR, Collier JG, Dollery CT, Ritter JM, Webb DJ. Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol London 1989;412:543-555.
17. [17] Jie K, Van Brummelen P, Van Zwieten PA. α-Adrenoceptors in blood vessels of the human forearm. Prog Pharmacol 1986;6:37-45.
18. [18] Munger KA, Jackson EK. Effects of selective A1 receptor blockade on glomerular hemodynamics: involvement of renin-angiotensin system. Am J Physiol 1994;267:F783-F790.
19. [19] Auguet M, Delaflotte S, Guillon JM, Chabrier PE, Braquet P. Different regulation of vascular tone by angiotensin II and endothelin-1 in rat aorta. Eur J Pharmacol 1991;196:21-27.
20. [20] Baylis C, Engels K, Samsell L, Harton P. Renal effects of acute endothelial-derived relaxing factor blockade are not mediated by angiotensin II. Am J Physiol 1993;264:F74-F78.
21. [21] Cockcroft JR, O'Kane KP, Webb DJ. Tissue angiotensin generation and regulation of vascular tone. Pharmacol Ther 1995;65:193-213.
22. [22] Luscher TF. Angiotensin, ACE-inhibitors and endothelial control of vasomotor tone. Basic Res Cardiol 1993;1:15-24.
23. [23] Stefas L, Levy BI. Effects of saralasin on arterial compliance in normotensive and hypertensive rats. Role of endothelium. Hypertension 1991;18:II30-26.
24. [24] Brunner HR, Nussberger J, Waeber B. Control of vascular tone by renin and angiotensin in cardiovascular disease. Eur Heart J 1993;:149-153.
25. [25] Dietz R, Waas W, Haberbosch W, et al. Modulation of coronary circulation and the cardiac matrix by the renin angiotensin system. Eur Heart J 1991;12:107-111.
26. [26] Lopez JJ, Lorell BH, Ingelfinger JR, et al. Distribution and function of cardiac angiotensin AT1-and AT2-receptor subtypes in hypertrophied rat hearts. Am J Physiol 1994;267:H844-H852.
27. [27] Sweet CS, Bradstreet DC, Berman RS, Jallard N, Saenz A, Weidler DJ. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994;7:1035-1040.
28. [28] Tamaki T, Nishiyama A, Yoshida H, et al. Effects of EXP3174, a non-peptide angiotensin II receptor antagonist, on renal hemodynamics and renal function in dogs. Eur J Pharmacol 1993;236:15-21.
29. [29] Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993;35:290-297.
30. [30] Zhang J, Pfaffendorf M, Zhang JS, Van Zwieten PA. A non-competitive type of angiotensin-receptor antagonism by losartan in renal artery preparations. Eur J Pharmacol 1994;252:337-340.
31. [31] Zhang JS, Van Meel JC, Pfaffendorf M, Van Zwieten PA. Characterization of the angiotensin II-receptor subtype in the longitudinal smooth muscle of the rat portal vein. Naunyn-Schmiedebergs Arch Pharmacol 1993;347:220-224.